Table II.
Node-splitting analysis.
| Name | Direct effect | Indirect effect | Overall | P-value |
|---|---|---|---|---|
| PASI 75 | ||||
| Adalimumab, MTX | −1.03 (−2.13, 0.09) | −0.13 (−1.44, 1.31) | −0.81 (−1.64, 0.10) | 0.28 |
| CSA 2.5 mg, CSA 5 mg | 2.15 (1.15, 3.13) | −0.55 (−2.24, 1.08) | 1.47 (0.44, 2.41) | 0.01 |
| CSA 2.5 mg, MTX | −0.51 (−1.71, 0.64) | 2.24 (0.71, 3.77) | 0.46 (−0.62, 1.48) | 0.01 |
| CSA 5 mg, MTX | 0.02 (−1.18, 1.24) | −2.70 (−4.23, −1.12) | −1.01 (−2.06, 0.07) | 0.01 |
| Etanercept 25 mg BIW, Etanercept 50 mg BIW | 0.64 (−0.08, 1.35) | −0.05 (−1.03, 0.89) | 0.41 (−0.27, 1.01) | 0.23 |
| Etanercept 50 mg BIW, Placebo | −3.02 (−3.57, −2.49) | −3.18 (−4.11, −2.32) | −3.03 (−3.51, −2.58) | 0.74 |
| Etanercept 50 mg BIW, Ustekinumab 45 mg | 0.46 (−0.61, 1.51) | 0.51 (−0.19, 1.18) | 0.48 (−0.15, 1.08) | 0.9 |
| Etanercept 50 mg BIW, Ustekinumab 90 mg | 0.77 (−0.29, 1.80) | 0.54 (−0.20, 1.20) | 0.62 (−0.00, 1.23) | 0.69 |
| Infliximab 3 mg, Placebo | −3.86 (−5.56, −2.35) | −3.95 (−5.09, −2.86) | −3.95 (−4.95, −3.01) | 0.94 |
| Infliximab 5 mg, MTX | −2.01 (−3.06, −1.04) | −2.18 (−3.45, −0.84) | −2.08 (−2.86, −1.25) | 0.83 |
| Infliximab 5 mg, Placebo | −4.83 (−5.77, −4.02) | −4.65 (−6.16, −3.25) | −4.73 (−5.50, −4.08) | 0.81 |
| MTX, Placebo | −2.53 (−3.72, −1.49) | −2.70 (−3.69, −1.78) | −2.66 (−3.50, −1.92) | 0.81 |
| Placebo, Ustekinumab 45 mg | 3.54 (2.96, 4.11) | 3.44 (2.39, 4.44) | 3.52 (2.99, 4.02) | 0.83 |
| Placebo, Ustekinumab 90 mg PASI 50 | 3.60 (2.97, 4.18) | 3.83 (2.83, 4.83) | 3.65 (3.11, 4.17) | 0.65 |
| PASI 50 | ||||
| Adalimumab, MTX | −1.51 (−2.41, −0.70) | 0.04 (−1.06, 1.18) | −1.10 (−2.03, −0.21) | 0.02 |
| Etanercept 25 mg BIW, Etanercept 50 mg BIW | 0.64 (−0.05, 1.38) | 0.73 (−0.20, 1.76) | 0.61 (0.02, 1.21) | 0.88 |
| Etanercept 50 mg BIW, Placebo | −3.13 (−3.66, −2.70) | −3.82 (−4.93, −2.73) | −3.22 (−3.78, −2.75) | 0.24 |
| Infliximab 3 mg, Placebo | −3.11 (−4.31, −1.87) | −2.93 (−4.01, −1.89) | −3.04 (−3.92, −2.25) | 0.82 |
| Infliximab 5 mg, MTX | −1.54 (−2.19, −0.88) | −3.08 (−4.17, −2.09) | −2.02 (−2.88, −1.37) | 0.01 |
| Infliximab 5 mg, Placebo | −4.45 (−5.18, −3.92) | −2.93 (−3.90, −1.90) | −4.13 (−4.79, −3.55) | 0.01 |
| MTX, Placebo | −1.42 (−2.34, −0.45) | −2.57 (−3.39, −1.73) | −2.11 (−2.85, −1.31) | 0.06 |
| PASI 90 | ||||
| Adalimumab, MTX | −2.04 (−3.04, −0.99) | −0.49 (−1.91, 0.86) | −1.67 (−2.58, −0.81) | 0.08 |
| Etanercept 25 mg BIW, Etanercept 50 mg BIW | 0.86 (0.14, 1.62) | −0.03 (−1.47, 1.35) | 0.75 (0.04, 1.39) | 0.24 |
| Etanercept 50 mg BIW, Placebo | −3.15 (−3.90, −2.45) | −3.34 (−4.48, −2.42) | −3.16 (−3.78, −2.63) | 0.76 |
| Etanercept 50 mg BIW, Ustekinumab 45 mg | 0.63 (−0.36, 1.70) | 0.99 (0.12, 1.83) | 0.82 (0.19, 1.48) | 0.53 |
| Etanercept 50 mg BIW, Ustekinumab 90 mg | 1.00 (0.01, 2.02) | 0.73 (−0.10, 1.59) | 0.90 (0.22, 1.52) | 0.61 |
| Infliximab 3 mg, Placebo | −4.12 (−8.54, −2.14) | −3.54 (−4.91, −2.48) | −3.56 (−4.64, −2.64) | 0.69 |
| Infliximab 5 mg, MTX | −1.80 (−2.74, −0.87) | −2.98 (−4.73, −1.47) | −2.07 (−2.97, −1.38) | 0.18 |
| Infliximab 5 mg, Placebo | −4.46 (−6.00, −3.43) | −3.33 (−4.77, −2.10) | −3.93 (−4.80, −3.18) | 0.2 |
| MTX, Placebo | −1.24 (−2.38, −0.25) | −2.30 (−3.43, −1.40) | −1.85 (−2.60, −1.07) | 0.12 |
| Placebo, Ustekinumab 45 mg | 4.15 (3.45, 4.86) | 3.78 (2.83, 4.68) | 3.99 (3.37, 4.61) | 0.37 |
| Placebo, Ustekinumab 90 mg | 3.99 (3.22, 4.77) | 4.32 (3.40, 5.28) | 4.07 (3.40, 4.70) | 0.44 |
PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly.